Seasonal and Treatment-Related Variation in 25-Hydroxy Vitamin D Concentration in Patients with Rheumatoid Arthritis

• Published in: Journal of clinical medicine 2024-02, Vol.13 (4), p.973
• Main Authors: Cieślewicz, Artur, Korzeniowska, Katarzyna, Grabańska-Martyńska, Katarzyna, Jabłecka, Anna, Hrycaj, Paweł
• Format: Article
• Language: English
• Subjects: Alfacalcidol; Autumn; Body mass index; Calcifediol; Care and treatment; Diagnosis; Drug therapy; Health aspects; Kinases; Nonsteroidal anti-inflammatory drugs; Patients; Remission (Medicine); Rheumatoid arthritis; Rheumatology; Statistical analysis; Summer; Vitamin D; Winter
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13040973

: 25-hydroxy vitamin D (25-OH-D) is a fat-soluble compound that plays many essential functions, including bone formation, neuromuscular functions, and prevention of osteoporosis and inflammation. Recent data indicate that its metabolites are associated with rheumatoid arthritis (RA) progression and neuropathic pain in RA patients. We aimed to assess the effect of RA pharmacotherapy and seasonal variation on serum levels of 25-OH-D in RA patients who received treatment with methotrexate (MTX) or leflunomide (LEF) for at least one year. : This study is a retrospective analysis of data collected from 101 patients with RA who received treatment for at least one year. All of them have supplemented 25-OH-D (2000 IU daily) for at least one year. : We observed a significant seasonal variation in 25-OH-D concentration ( = 0.004). Moreover, there were significant differences ( = 0.03) between LEF (50.63 ± 17.73 ng/mL) and MTX (34.73 ± 14.04 ng/mL) treatment groups, but only for the summer population. A correlation was observed between 25-OH-D and RA duration-once again, in the summer population (the whole group-r = -0.64; treatment subgroups-r = -0.82 for LEF and -0.61 for MTX). Deficiency of 25-OH-D (below 20 ng/mL) was confirmed in 28.7% of patients, while 18.8% had suboptimal 25-OH-D levels (20-30 ng/mL). : Our results showed that both RA pharmacotherapy and seasonal variation affect the serum levels of 25-OH-D in patients with active RA.